Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Rises By 365.8%

TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 417,400 shares, an increase of 365.8% from the April 30th total of 89,600 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 9th.

TScan Therapeutics Trading Up 31.3 %

TScan Therapeutics stock traded up $0.76 during midday trading on Friday, hitting $3.19. 3,685,387 shares of the stock were exchanged, compared to its average volume of 963,053. TScan Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $6.03. The stock has a market capitalization of $77.28 million, a price-to-earnings ratio of -0.85 and a beta of 0.31. The stock’s 50-day simple moving average is $2.61 and its 200 day simple moving average is $2.37. The company has a current ratio of 7.18, a quick ratio of 7.18 and a debt-to-equity ratio of 0.38.

TScan Therapeutics (NASDAQ:TCRX – Get Rating) last announced its earnings results on Wednesday, March 8th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.05). The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $2.63 million. TScan Therapeutics had a negative return on equity of 68.23% and a negative net margin of 419.38%. On average, equities analysts anticipate that TScan Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter worth about $32,000. Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics in the 3rd quarter worth about $34,000. Renaissance Technologies LLC purchased a new stake in shares of TScan Therapeutics in the 1st quarter worth about $37,000. LPL Financial LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter worth about $50,000. Finally, Millennium Management LLC purchased a new stake in shares of TScan Therapeutics in the 4th quarter worth about $31,000. 48.21% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

(Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.